Abstract
No public abstract is available from the verified source records.
Pasquale Pisapia, Oriol Mirallas, Erick F. Saldanha, Roberto Borea
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cancer in a drop: advances in liquid biopsy in 2024
10.1016/j.critrevonc.2025.104776 · 2025
Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection
10.1038/s41568-025-00795-x · 2025
Unresolved referenced work
2026
Blood-based circulating tumour DNA (ctDNA) tests for colorectal cancer screening: systematic review and meta-analysis of diagnostic accuracy
10.1016/j.critrevonc.2026.105289 · 2026
Genomic signatures in red blood cell DNA enable early non-invasive detection of colorectal neoplasia: a multicenter clinical study [abstract]
2026
Urinary extracellular vesicle microRNA profiling enables noninvasive early detection and prognostic stratification of lung cancer [abstract]
2026
Non-invasive early detection of cancer-predisposing liver diseases using genome-wide cfDNA fragmentomes [abstract]
2026
Enhanced early detection of pancreatic cancer using a multi-analyte liquid biopsy approach [abstract]
2026
Valsamo (Elsa) Anagnostou. Serial plasma comprehensive genomic profiling detects therapy resistance and guides management of metastatic non-small cell lung cancer [abstract]
2026
Circulating tumor DNA (ctDNA) clearance dynamics in microsatellite instability-high metastatic (MSI-H) colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI) [abstract]
2026
Unresolved referenced work
2026
Unresolved referenced work
2024
Early findings from MONITOR-Breast: ctDNA dynamics during neoadjuvant therapy using an ultrasensitive MRD assay [abstract]
2026
Molecular residual disease (MRD) interception in locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC): the MERIDIAN Phase II trial [abstract]
2026
ctDNA clearance as a prognostic biomarker in ES-SCLC: insights from the LUMINANCE phase IIIb study [abstract]
2026
ctDNA as a prognostic and pharmacodynamic biomarker following first- or later-line treatment of advanced NSCLC with BNT116 + cemiplimab [abstract]
2026
Unresolved referenced work
2026
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: results from a phase 1/2 study [abstract]
2026
AXL mRNA overexpression in CTCs as a new potential liquid biopsy biomarker in NSCLC [abstract]
2026
Circulating tumor cell (CTC) informed pipeline for rapid personalization of synergistic cytokine-armed CAR-NK cell therapy in PDAC [abstract]
2026
Computational ranking-guided discovery of Plexin-B2 as a driver of circulating tumor cell clusters and AI-facilitated neutralization to prevent and inhibit metastasis [abstract]
2026
Liquid biopsies come of age: towards implementation of circulating tumour DNA
10.1038/nrc.2017.7 · 2017
Circulating mutant DNA to assess tumor dynamics
10.1038/nm.1789 · 2008
Analysis of circulating tumor DNA to monitor metastatic breast cancer
10.1056/nejmoa1213261 · 2013
Integrating liquid biopsies into the management of cancer
10.1038/nrclinonc.2017.14 · 2017
Current and future perspectives of liquid biopsies in genomics-driven oncology
10.1038/s41576-018-0071-5 · 2019
Molecular profiling across 80,000 patients with lung cancer
10.1016/j.jtho.2026.103695 · 2026
Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: evidence from a real-world cohort of patients with advanced common solid malignancies
2025
Feasibility of plasma ctDNA for detecting brain metastasis-specific alterations in lung cancer [abstract]
2026
A phase II trial of adjuvant PD-1 blockade with endocrine therapy in hormone receptor positive inflammatory breast cancer: circulating biomarkers and molecular correlates of clinical outcomes [abstract]
2026
Unlocking endocrine resistance: Co-targeting KAT6 and ER with prifetrastat (PF-07248144) and fulvestrant drives tumor and ctDNA response in ER+/HER2− metastatic breast cancer [abstract]
2026
No additional external references are available.